Recursion Pharmaceuticals

Recursion Pharmaceuticals Overview

Founded 2013
Founded
Status Private
Employees 165
Employees
Latest Deal Type Debt
Latest Deal Amount $27M
Latest Deal Amount
Investors 39

Recursion Pharmaceuticals General Information

Description

Operator of a drug-discovery company intended to discover potential drugs for rare genetic diseases, inflammatory diseases, infectious diseases and immuno-oncology. The company combines artificial intelligence, automation and experimental biology to discover new therapeutic opportunities for rare genetic diseases and uses high-throughput genetic manipulation to model many diseases in multiple human cell types quickly, enabling healthcare providers to treat patients easily.

Contact Information

Formerly Known As
Recursion Pharmaceuticals, LLC
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 41 South Rio Grande Street
  • Salt Lake City, UT 84101
  • United States
+1 (385) 000-0000

Recursion Pharmaceuticals Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Recursion Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Debt - General 01-Sep-2019 $27M 00000 Completed Clinical Trials - General
8. Later Stage VC (Series C) 13-Aug-2019 00000 00000 00000 Completed Clinical Trials - General
7. Grant 08-Nov-2018 00.00 00000 Completed Pre-Clinical Trials
6. Debt - General 05-Jun-2018 000.00 00000 Completed Pre-Clinical Trials
5. Grant 07-May-2018 000.00 Completed Pre-Clinical Trials
4. Early Stage VC (Series B) 03-Oct-2017 0000 000.00 00000 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 07-Feb-2017 0000 000.00 0000 Completed Startup
2. Grant 25-Feb-2015 $1.5M $170K Completed Startup
1. Seed Round 15-Aug-2014 $170K $170K Completed Startup

Recursion Pharmaceuticals Cap Table

To view Recursion Pharmaceuticals‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A1 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00

Recursion Pharmaceuticals Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
AI Therapeutics Venture Capital-Backed Guilford, CT 00 0000 00000000000 0000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 0000000000 0 00000
00000 00000000 Venture Capital-Backed San Francisco, CA 00 000.00 00000000000 000.00
000000 00000000000 Corporation PA 000 000.00 00000000 000.00

Recursion Pharmaceuticals Executive Team (21)

Name Title Board Seat Contact Info
Christopher Gibson Ph.D Co-Founder, Chief Executive Officer & Board Member
Tina Larson Chief Operating Officer & President
Michael Secora Ph.D Chief Financial Officer
Ben Mabey Interim Chief Technology Officer & Vice President of Engineering
Sharath Hegde Chief Scientific Officer

3 Former Executives

Recursion Pharmaceuticals Board Members (13)

To view Recursion Pharmaceuticals‘s full board member team, request access »
Name Representing Role Since
Alaa Halawa Mubadala Investment Company Board Observer 000 0000
Blake Borgeson Ph.D Recursion Pharmaceuticals Co-Founder, Scientific Advisor & Board Member 000 0000
Christopher Gibson Ph.D Recursion Pharmaceuticals Co-Founder, Chief Executive Officer & Board Member 000 0000
Dean Li Ph.D Recursion Pharmaceuticals Co-Founder & Board Member 000 0000
James Hardiman Data Collective Board Observer 000 0000

Recursion Pharmaceuticals Investors (39)

To view Recursion Pharmaceuticals‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Baillie Gifford Asset Manager Minority 000 0000 000000 0
Intermountain Ventures Corporate Venture Capital Minority 000 0000 000000 0
Proioxis Ventures Venture Capital Minority 000 0000 000000 0
Regents of the University of Minnesota Corporation Minority 000 0000 000000 0
Scottish Mortgage Investment Trust Other Minority 000 0000 000000 0

Ready to get started?

Request a free trial